The American journal of medicine
-
The placebo effect is defined as any improvement of symptoms or signs following a physically inert intervention. Its effects are especially profound in relieving subjective symptoms such as pain, fatigue, and depression. Present to a variable extent in all therapeutic encounters, this effect is intensified by hands-on contact with close verbal communication between caregiver and recipient. ⋯ Physicians must be skeptical about apparent "responses" to treatments, using the information described herein to better understand what we are-or are not-accomplishing to provide the best possible outcomes for our patients. Less well studied, the "nocebo effect" defines negative responses to placebo interventions. This latter effect may be quite profound and likely is causative in many maladies believed to have psychic origins.
-
Multicenter Study Observational Study
Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE).
Current guidelines recommend early oral beta-blocker administration in the management of acute coronary syndromes for patients who are not at high risk of complications. ⋯ Early beta-blocker use is common in patients presenting with ST-elevation myocardial infarction, with oral administration being the most prevalent. Oral beta-blockers were associated with a decrease in the risk of cardiogenic shock, ventricular arrhythmias, and acute heart failure. However, the early receipt of any form of beta-blockers was associated with an increase in hospital mortality.
-
The purpose of this study was to examine the impact of a multifaceted, clinical decision support (CDS)-enabled intervention on magnetic resonance imaging (MRI) use in adult primary care patients with low back pain. ⋯ CDS and associated accountability tools may reduce potentially inappropriate imaging in patients with low back pain.
-
Current guidelines strongly recommend that oral anticoagulation should be offered to patients with atrial fibrillation and ≥1 stroke risk factors. The guidelines also recommend that oral anticoagulation still should be used in the presence of stroke risk factors irrespective of rate or rhythm control. ⋯ The EURObservational Research Programme on Atrial Fibrillation Pilot Survey provides contemporary data on oral anticoagulation prescribing by European cardiologists for atrial fibrillation. Although the uptake of oral anticoagulation (mostly vitamin K antagonist therapy) has improved since the Euro Heart Survey a decade ago, antiplatelet therapy is still commonly prescribed, with or without oral anticoagulation, whereas elderly patients are commonly undertreated with oral anticoagulation.